Arno Therapeutics' Executive Selected to Chair World CDx Boston 2014

FLEMINGTON, N.J., Sept. 18, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB: ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that David Jackson, Ph.D., Vice President of Diagnostics & Companion Diagnostics, has been selected as Chair of World CDx Boston 2014, the 5th annual summit of this meeting, being held September 23-25, 2014 in Boston, Mass.

Dr. Jackson is responsible for the management of a novel companion diagnostic co-development program with Leica Biosystems Ltd (Newcastle UK) manufacturing the companion diagnostic kit to support the development and global registration of onapristone, a targeted oncology therapeutic directed at the activated progesterone receptor. He also leads Arno's work with Clarient Diagnostic Services, Inc. (a GE Healthcare Company) performing diagnostic laboratory services for the clinical development of onapristone.

In addition to chairing the meeting, Dr. Jackson will make a presentation entitled, "Strategic Rx-CDx Co-Development & Commercialization," to discuss the overall approach to commercializing companion diagnostics on a global level. Dr. Jackson will also offer his deep experience and insight regarding designing a companion diagnostic strategy for drug developers, aligning drug and diagnostic timelines to ensure drug is launched on time and managing companion diagnostic partnerships and alliances.

Details of Dr. Jackson's presentations are as follows:

"It is an honor to have been selected as Chair of this prestigious meeting," commented Dr. Jackson. "World CDx Boston offers a unique and dynamic platform for discussing with key industry members the new opportunities and challenges presented in the precision medicine space. The meeting historically brings together expertise across the industry to provide thoughtful and meaningful discussion to further develop successful companion diagnostic strategies and I am looking forward to being a part of this year's meeting."

About Arno Therapeutics

Arno Therapeutics is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer.  Arno has exclusive worldwide rights to develop and market three innovative anti-cancer product candidates.  These compounds are in clinical or preclinical development as product candidates to treat hematologic malignancies and solid tumors.  For more information about the company, please visit www.arnothera.com. 

CONTACT: The Ruth Group
         Lee Roth (investors)
         [email protected]
         (646) 536-7012

         Kirsten Thomas (media)
         [email protected]
         (646) 536-7014

         Arno Therapeutics
         Lawrence Kenyon
         [email protected]
         (862) 703-7171

You May Also Be Interested In

• BlockDAG’s 72-Hour Price Offer Draws Crypto Whales’ Attention While XRP Slows Down & SOL Faces Key Resistance
• Solana Tests Support & XRP Consolidates, While BlockDAG Takes Center Stage Ahead of Exchange Launch 
• Formosa Plastics Corporation, U.S.A. Announces Merger With Formosa Industries Corporation